C12 NBD Globotriaosylceramide 

C12 NBD galactosylceramide is a biologically active derivative of galactosylceramide that is tagged with a fluorescent C12 nitrobenzoxadiazole (C12 NBD) group. C12 NBD galactosylceramide has been used to detect ceramide trihexoside^[1].

C12 NBD globotriaosylceramide accumulates in human umbilical vascular endothelial cells (HUVECs) treated with the α-galactosidase A inhibitor in a concentration-dependent manner^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1146.32

C₅₄H₉₁N₅O₂₁

2692623-26-8

525

485

O=C(CCCCCCCCCCCNC1=CC=C(C2=NON=C12)[N+]([O-])=O)N[C@@H](CO[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O[C@@]4(O[C@@H]([C@@H]([C@@H]([C@H]4O)O)O[C@@]5([C@@H]([C@H]([C@H]([C@H](O5)CO)O)O)O)[H])CO)[H])O)O)[C@@H](/C=C/CCCCCCCCCCCCC)O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Kassiani Kytidou, et al. Nicotiana benthamiana α-galactosidase A1.1 can functionally complement human α-galactosidase A deficiency associated with Fabry disease. J Biol Chem. 2018 Jun 29;293(26):10042-10058.  [Content Brief]

  [2]. Janet Hsu, et al. Enhanced endothelial delivery and biochemical effects of α-galactosidase by ICAM-1-targeted nanocarriers for Fabry disease. J Control Release. 2011 Feb 10;149(3):323-31.  [Content Brief]